Finance

Lists
Q3 2026 earnings • released • EPS miss -107.35% • Revenue miss -9.82%
See results
IMCR:NASDAQ
Immunocore Holdings PLC - ADR
$31.73
+2.39%
(+0.74) 1D
$30.59
-3.59% (-1.14)
After hours
Closed: Nov 9, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMCR...
Open
$30.99
High
$31.91
Low
$30.52
Mkt. cap
1.66B
Avg. vol.
532.81K
Volume
554.35K
52-wk high
$40.71
52-wk low
$27.50
EPS
-$0.37
Beta
0.82
Shares outstanding
51.50M
No. of employees
524
Open
$30.99
High
$31.91
Low
$30.52
Mkt. cap
1.66B
Avg. vol.
532.81K
Volume
554.35K
52-wk high
$40.71
52-wk low
$27.50
EPS
-$0.37
Beta
0.82
Shares outstanding
51.50M
No. of employees
524
News stories
From web sources and news partners
Profile
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
About Immunocore Holdings PLC - ADR
CEOBahija Jallal
Employees524
Founded2008
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteimmunocore.com
Analyst ratings
Based on 5 analysts giving stock ratings to IMCR in the past 3 months
Buy
Buy
3
Hold
2
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for IMCR in the last 3 months.
Highest
Current $31.73
$100.00 (+215.16%)
Average
$56.50 (+78.06%)
Lowest
$33.00 (+4.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Hold
Reiterated
$43.00
+35.5%
11/09/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$100.00
+215.2%
11/04/2026
Graig Suvannavejh
Mizuho Securities
Hold
Maintained
$33.00
+4%
10/29/2026
Rajan Sharma
Goldman Sachs
Buy
Maintained
-
-
10/28/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$50.00
+57.6%
08/21/2026
Gil Blum
Needham
Buy
Maintained
$75.00
+136.4%
08/06/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
05/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$60.00
+89.1%
05/06/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$86.00
+171%
04/20/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$60.00
+89.1%
04/14/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
$33.00
+4%
03/15/2026
Last report
Nov 6, 2026
Fiscal period
Q3 2026
-$0.28 / -$0.14
-107.35%miss
Revenue / Est. (USD)
102.22M / 113.36M
-9.82%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
104.48M
106.68M
115.93M
102.22M
Cost of goods sold
81.52M
434.00K
75.03M
676.00K
Cost of revenue
81.52M
434.00K
75.03M
676.00K
Research and development expenses
-
61.11M
-
74.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.64M
37.85M
43.89M
40.45M
Operating expense
22.92M
98.96M
43.89M
115.16M
Total operating expenses
104.44M
99.40M
118.92M
115.83M
Operating income
37.00K
7.28M
-3.00M
-13.61M
Other non operating income
-15.22M
-
-
763.00K
EBT including unusual items
-15.79M
13.27M
-514.00K
-14.07M
EBT excluding unusual items
-15.79M
11.50M
-3.58M
-14.07M
Income tax expense
14.27M
301.00K
294.00K
153.00K
Effective tax rate
-90.33%
2.27%
-57.20%
-1.09%
Other operating expenses
-19.73M
-
-
-
Net income
-30.06M
12.97M
-808.00K
-14.22M
Net profit margin
-28.77%
12.16%
-0.70%
-13.91%
Earnings per share
-0.60
0.25
-0.02
-0.28
Interest and investment income
3.91M
3.42M
3.58M
3.61M
Interest expense
-3.05M
-3.05M
-3.06M
-3.06M
Net interest expenses
853.00K
367.00K
520.00K
547.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
871.00K
8.23M
-1.97M
-12.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps